polymyalgia rheumatica
Information
- Disease name
- polymyalgia rheumatica
- Disease ID
- DOID:853
- Description
- "A collagen disease that is characterized by pain, stiffness, and tenderness of the proximal muscle groups including the shoulder, pelvic girdle and the neck." [url:https\://medlineplus.gov/polymyalgiarheumatica.html]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04519580 | Active, not recruiting | Improved Diagnostics and Monitoring of Polymyalgia Rheumatica | September 14, 2020 | June 30, 2027 | |
| NCT00524381 | Completed | Phase 3 | Etanercept Treatment in the Early Course of Polymyalgia Rheumatica | August 2007 | September 2009 |
| NCT00836810 | Completed | Phase 2/Phase 3 | Timed Release Tablet Prednisone in Polymyalgia Rheumatica | October 2009 | March 2011 |
| NCT00847236 | Completed | Protocol For The Quantitation Of Pain In The Diagnosis Of Polymyalgia Rheumatica | January 2009 | August 2013 | |
| NCT00138983 | Completed | Phase 3 | Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. | May 2000 | November 2003 |
| NCT01169597 | Completed | Phase 4 | Short Term Efficacy of a Starting Dose of 12.5 mg of Prednisone in Polymyalgia Rheumatica Patients | January 2009 | May 2010 |
| NCT05681676 | Completed | Melanocortin Gene Expression in Lymphocytes of Polymyalgia Patients | March 1, 2012 | December 1, 2022 | |
| NCT01713842 | Completed | Phase 2 | Tocilizumab Effect iN pOlymyalgia Rheumatica | July 2012 | October 2014 |
| NCT04799262 | Completed | Phase 2 | Tofacitinib as a GC Sparing Agent for Polymyalgia Rheumatica | January 1, 2021 | May 1, 2022 |
| NCT04727879 | Completed | N/A | Immunopathology of Polymyalgia Rheumatica on Shoulder Bursae's Biopsies | April 7, 2021 | August 13, 2022 |
| NCT02888496 | Completed | Lymphocyte and Cytokine Disturbances in Polymyalgia Rheumatica | January 2015 | June 2015 | |
| NCT03263715 | Completed | Phase 3 | A Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE) | November 24, 2017 | June 2, 2020 |
| NCT03941184 | Completed | Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity | January 1, 1995 | November 10, 2020 | |
| NCT02908217 | Completed | Phase 3 | Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE | February 15, 2017 | November 12, 2020 |
| NCT04239521 | Completed | The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata | October 1, 2020 | November 28, 2022 | |
| NCT06172361 | Not yet recruiting | Phase 3 | Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia Rheumatica | January 15, 2024 | January 30, 2026 |
| NCT06460142 | Recruiting | Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic | September 1, 2023 | September 30, 2027 | |
| NCT03840928 | Recruiting | PatientSpot Formerly Known as ArthritisPower | April 1, 2015 | March 1, 2025 | |
| NCT04102930 | Recruiting | Clinical and Immunogenetic Characterization of Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR) | June 10, 2005 | February 1, 2025 | |
| NCT04402086 | Recruiting | Rheumatology Patient Registry and Biorepository | August 4, 2020 | June 1, 2030 | |
| NCT05435781 | Recruiting | Phase 4 | Effect of Supplemental Hydrocortisone During Stress in Prednisolone-induced Adrenal Insufficiency | June 7, 2022 | March 1, 2028 |
| NCT05436652 | Recruiting | Phase 2 | A Trial of Prednisolone in Combination With SPI-62 or Placebo in Subjects With Polymyalgia Rheumatica (PMR) | July 22, 2022 | July 31, 2024 |
| NCT05533125 | Recruiting | Phase 3 | Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Recently Diagnosed | February 1, 2023 | January 2027 |
| NCT05533164 | Recruiting | Phase 3 | Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse | February 9, 2023 | January 2027 |
| NCT05542316 | Recruiting | Validation of the PMR Activity Score and Evolution of Patient-reported Outcomes in Patients With Polymyalgia Rheumatica | July 1, 2022 | October 1, 2024 | |
| NCT05636501 | Recruiting | N/A | Treat-to-target Prednisolon Taper in Patients With Polymyalgia Rheumatica | January 12, 2023 | November 2026 |
| NCT05767034 | Recruiting | Phase 3 | Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) | March 22, 2023 | February 17, 2026 |
| NCT05935709 | Recruiting | DANIsh VASculitis Database (DANIVAS) | November 10, 2023 | December 31, 2051 | |
| NCT06011512 | Recruiting | Risk of Diabetes Mellitus in Patients With Giant Cell Arthritis and Polymyalgia Rheumatica. | August 1, 2023 | June 1, 2026 | |
| NCT06130540 | Recruiting | Phase 1 | Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR | March 27, 2024 | July 25, 2025 |
| NCT06281236 | Recruiting | Phase 1 | A Trial of Prednisolone in Combination With SPI-62 in Participants With Polymyalgia Rheumatica (PMR) | February 22, 2024 | October 1, 2024 |
| NCT06331312 | Recruiting | Phase 3 | Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) | April 10, 2024 | May 8, 2028 |
| NCT01364389 | Terminated | Phase 2 | A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica | February 14, 2011 | January 29, 2013 |
| NCT03600818 | Terminated | Phase 3 | Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica | October 9, 2018 | May 19, 2021 |
| NCT03656627 | Terminated | Phase 1 | Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease | June 27, 2019 | March 18, 2021 |
| NCT02702778 | Terminated | Phase 2 | Delayed Release Prednisone in PMR | February 2016 | March 31, 2017 |
| NCT01821040 | Terminated | Phase 3 | A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMR | March 2013 | April 2014 |
| NCT04972968 | Terminated | Phase 2 | A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154 | September 9, 2021 | July 24, 2023 |
| NCT00982332 | Unknown status | N/A | Efficacy of Micro-Pulse Steroid Therapy as Induction Therapy in Patients With Polymyalgia Rheumatica | March 2010 | March 2012 |
| NCT04664465 | Unknown status | PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS | March 18, 2021 | March 18, 2024 | |
| NCT05312944 | Unknown status | Polymyalgia Rheumatica Associated to Primary Sjogren Syndrome | March 2, 2021 | March 2, 2023 | |
| NCT03632187 | Unknown status | Phase 3 | Abatacept in earLy Onset Polymyalgia Rheumatica: Study ALORS | December 13, 2018 | July 21, 2022 |
| NCT01423591 | Unknown status | Phase 3 | Infliximab Therapy in Patients With Refractory Polymyalgia Rheumatica | June 2007 | December 2011 |
| NCT03576794 | Unknown status | Phase 3 | Treatment With Leflunomide in Patients With Polymyalgia Rheumatica | March 1, 2019 | November 1, 2022 |
| NCT04062006 | Unknown status | Phase 2 | Low-dose Interleukin-2 Treatment on Polymyalgia Rheumatica | August 31, 2019 | June 30, 2021 |
| NCT02985424 | Unknown status | Polymyalgia Rheumatica and Giant Cell Arteritis | May 2017 | February 2020 | |
| NCT02899026 | Withdrawn | Phase 3 | Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica | March 15, 2018 | August 26, 2021 |
- Disase is a (Disease Ontology)
- DOID:854
- Cross Reference ID (Disease Ontology)
- ICD10CM:M35.3
- Cross Reference ID (Disease Ontology)
- ICD9CM:725
- Cross Reference ID (Disease Ontology)
- MESH:D011111
- Cross Reference ID (Disease Ontology)
- NCI:C85018
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:202834009
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0032533
- MedGen concept unique identifier (MedGen Concept name)
- C0032533
- MedGen unique identifier (MedGen Concept name)
- 19393
- ICD10 preferred id (Insert disease from ICD10)
- D0010475
- ICD10 class code (Insert disease from ICD10)
- M35.3
- MeSH unique ID (MeSH (Medical Subject Headings))
- D011111